Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 9/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26167881 | 0.87 | P2RX7 (0.40) | P2RX7AVPR2EPHX2 | |
| SCHEMBL20382338 | 0.86 | — | — | |
| SCHEMBL13198116 | 0.86 | KLK1 (0.32) | — | |
| SCHEMBL9715241 | 0.81 | F2 (0.38) | — | |
| SCHEMBL17586136 | 0.78 | SLC7A5 (0.38) | F10 | |
| Hydrochloric Acid SCHEMBL9715397 | 0.78 | F10 (0.42) | F10 | |
| SCHEMBL27098277 | 0.75 | GRIN1 (0.32) | F10KLKB1 | |
| SCHEMBL3867866 | 0.74 | ALDH1A1 (0.45) | — | |
| SCHEMBL26729992 | 0.73 | LMNA (0.37) | — | |
| SCHEMBL7327634 | 0.71 | HPGD (0.46) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160074541-A1 | Prosthetic Compounds for Labeling Internalizing Biomolecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-17 | — | — | US | disclosed |
| US-20110280803-A1 | RADIOIODINATION METHOD | GE HEALTHCARE UK LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280803-A1 | RADIOIODINATION METHOD | TPO, SSTR5, DAO | P2RX7 4471/4885AVPR2 105/4885F10 3516/4885 |
| US-20160074541-A1 | Prosthetic Compounds for Labeling Internalizing Biomolecules | CD47, CD2, CD22 | P2RX7 2431/4885AVPR2 4317/4885F10 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.